BRC
TRIB

Bell Rock Capital’s Trinity Biotech TRIB Stock Holding History

Bell Rock Capital’s Portfolio TRIB Stock Details TRIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-60
Closed -$2K – 425
2017
Q2 		$2K Hold
60
– – ﹤0.01% 398
2017
Q1 		$2K Hold
60
– – ﹤0.01% 341
2016
Q4 		$2K Buy
+60
New +$2.07K ﹤0.01% 338

Other funds holding TRIB

PIM
Paradice Investment Management Denver, Colorado $532M AUM 29.6% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
LAM
Lapides Asset Management Greenwich, Connecticut $153M AUM 9.03% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
FWSM
First Wilshire Securities Management Pasadena, California $444M AUM 42.88% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
SCM
Stonehill Capital Management New York $197M AUM 96.45% 1-Year Est. Return
HAIM
Hunter Associates Investment Management Pittsburgh, Pennsylvania $756M AUM 19.99% 1-Year Est. Return

Bell Rock Capital's TRIB Position: Q3 2017 in Review

Bell Rock Capital sold out of Trinity Biotech (TRIB) in Q3 2017, closing a stake of 60 shares — an estimated $2K sold.

Bell Rock Capital first reported a position in TRIB in Q4 2016 and held it in 3 quarters. The position peaked at $2K in Q2 2017. 52 funds tracked by Wall St. Rank hold TRIB as of Q3 2017.

  • Bell Rock Capital reported no remaining Trinity Biotech position as of Q3 2017 after selling out during the quarter.
  • Bell Rock Capital sold 60 Trinity Biotech shares in Q3 2017, an estimated $2K.
  • Bell Rock Capital first reported a position in Trinity Biotech in Q4 2016 and held it in 3 quarters.
  • Bell Rock Capital's Trinity Biotech position peaked at $2K in Q2 2017.
  • 52 funds tracked by Wall St. Rank held Trinity Biotech as of Q3 2017.

Based on Bell Rock Capital's 13F filing for Q3 2017, filed 6 Dec 2018.